These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25878002)

  • 1. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.
    Freedman MS; Comi G; De Stefano N; Barkhof F; Polman CH; Uitdehaag BM; Lehr L; Stubinski B; Kappos L
    Mult Scler Relat Disord; 2014 Mar; 3(2):147-55. PubMed ID: 25878002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
    Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
    Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.
    Comi G; Martinelli V; Rodegher M; Moiola L; Leocani L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Preziosa P; Ravnborg M; Rieckmann P; Rocca MA; Wynn D; Young C; Filippi M
    Mult Scler; 2013 Jul; 19(8):1074-83. PubMed ID: 23234810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of early diagnosis of multiple sclerosis.
    Miller JR
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S4-11. PubMed ID: 15253684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
    Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
    Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinically isolated syndrome: prognostic markers for conversion to multiple sclerosis and initiation of disease-modifying therapy].
    Kohriyama T
    Rinsho Shinkeigaku; 2011 Mar; 51(3):179-87. PubMed ID: 21485162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
    Barkhof F; Rocca M; Francis G; Van Waesberghe JH; Uitdehaag BM; Hommes OR; Hartung HP; Durelli L; Edan G; Fernández O; Seeldrayers P; Sørensen P; Margrie S; Rovaris M; Comi G; Filippi M;
    Ann Neurol; 2003 Jun; 53(6):718-24. PubMed ID: 12783417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group.
    Doggrell SA
    Expert Opin Pharmacother; 2010 May; 11(7):1225-30. PubMed ID: 20230307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
    Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New options for early treatment of multiple sclerosis.
    Tintoré M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
    O'Connor P; Kinkel RP; Kremenchutzky M
    Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
    Thrower BW
    Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.
    Sombekke MH; Wattjes MP; Balk LJ; Nielsen JM; Vrenken H; Uitdehaag BM; Polman CH; Barkhof F
    Neurology; 2013 Jan; 80(1):69-75. PubMed ID: 23243070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
    Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
    N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis.
    Kennedy P
    J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S3-13. PubMed ID: 24217189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.